{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:53:58Z","timestamp":1791500038205,"version":"4.3.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtha.2026.04.012","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T08:56:07Z","timestamp":1776243367000},"page":"3711-3722","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["TQB3473, a novel spleen tyrosine kinase inhibitor for primary immune thrombocytopenia: a single-arm, open-label, multicenter phase 1 study"],"prefix":"10.1016","volume":"24","author":[{"given":"Bingjie","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiejun","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangzhou","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5259-1429","authenticated-orcid":false,"given":"Hu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.04.012_bib1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2141.2009.07717.x","article-title":"Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and\/or decreased platelet production","volume":"146","author":"Nugent","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.04.012_bib2","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMra010501","article-title":"Immune thrombocytopenic purpura","volume":"346","author":"Cines","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.04.012_bib3","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1001\/archinte.160.11.1630","article-title":"The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts","volume":"160","author":"Cohen","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jtha.2026.04.012_bib4","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/bloodadvances.2020001446","article-title":"Risk factors for skin, mucosal, and organ bleeding in adults with primary ITP: a nationwide study in Japan","volume":"4","author":"Hato","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2026.04.012_bib5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/asheducation-2015.1.237","article-title":"Bleeding complications in immune thrombocytopenia","volume":"2015","author":"Arnold","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtha.2026.04.012_bib6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3324\/haematol.2020.248385","article-title":"Fc\u03b3RI and Fc\u03b3RIII on splenic macrophages mediate phagocytosis of anti-glycoprotein IIb\/IIIa autoantibody-opsonized platelets in immune thrombocytopenia","volume":"106","author":"Norris","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2026.04.012_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/bjh.12480","article-title":"Cellular immune dysfunction in immune thrombocytopenia (ITP)","volume":"163","author":"McKenzie","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.04.012_bib8","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1080\/10245332.2018.1435021","article-title":"Immune dysregulation in primary immune thrombocytopenia patients","volume":"23","author":"Zhang","year":"2018","journal-title":"Hematology"},{"key":"10.1016\/j.jtha.2026.04.012_bib9","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2026.04.012_bib10","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3390\/medicina56120667","article-title":"Immune thrombocytopenia (ITP): current limitations in patient management","volume":"56","author":"Terrell","year":"2020","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.jtha.2026.04.012_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/ajh.24234","article-title":"Is ITP a thrombophilic disorder?","volume":"91","author":"Rodeghiero","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2026.04.012_bib12","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1016\/S2665-9913(20)30033-3","article-title":"Lessons for rituximab therapy in patients with rheumatoid arthritis","volume":"2","author":"Garcia-Montoya","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jtha.2026.04.012_bib13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijsu.2013.11.017","article-title":"Benefits and risks of splenectomy","volume":"12","author":"Weledji","year":"2014","journal-title":"Int J Surg"},{"key":"10.1016\/j.jtha.2026.04.012_bib14","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/bloodadvances.2020002003","article-title":"Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia","volume":"4","author":"Robak","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2026.04.012_bib15","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2026.04.012_bib16","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.3390\/ijms25042163","article-title":"Current understanding of immune thrombocytopenia: a review of pathogenesis and treatment options","volume":"25","author":"Mititelu","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtha.2026.04.012_bib17","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2026.04.012_bib18","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/bjh.18582","article-title":"Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: a phase 3, placebo-controlled, double-blind, parallel-group study","volume":"200","author":"Kuwana","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.04.012_bib19","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1016\/S2352-3026(24)00139-X","article-title":"Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"11","author":"Hu","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2026.04.012_bib20","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S2352-3026(23)00034-0","article-title":"Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b\/2 study","volume":"10","author":"Liu","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2026.04.012_bib21","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1182\/blood-2004-03-1168","article-title":"Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications","volume":"104","author":"Kojouri","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.04.012_bib22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12185-015-1837-6","article-title":"Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim","volume":"102","author":"Cines","year":"2015","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2026.04.012_bib23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/toxsci\/kfac015","article-title":"Acute Liver Failure Study Group. Proteomics indicates lactate dehydrogenase is prognostic in acetaminophen-induced acute liver failure patients and reveals altered signaling pathways","volume":"187","author":"Vazquez","year":"2022","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.jtha.2026.04.012_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2025.1662585","article-title":"Determinants of abnormal liver-related biomarkers in adult COVID-19 patients","volume":"15","author":"Zhang","year":"2026","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jtha.2026.04.012_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100647","article-title":"Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: real-world recommendations","volume":"41","author":"Zaja","year":"2020","journal-title":"Blood Rev"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626002576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626002576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:41:00Z","timestamp":1791499260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626002576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1538783626002576"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.04.012","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TQB3473, a novel spleen tyrosine kinase inhibitor for primary immune thrombocytopenia: a single-arm, open-label, multicenter phase 1 study","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}